Benzinga | Jun 8, 2021 03:34PM EDT

VYNE Therapeutics Granted Patent On Use Of NK-1 Receptor Antagonist Serlopitant In Pruritus

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6721&f=G&l=50&d=PTXT&p=135&S1=20210608&OS=20210608&RS=20210608